GlassScriptPhysician profile
Andrew J Blank
NPI 1184720542
$5,788.76
in general payments reported to CMS, 2019-2025
60 companies · $962 in 2025
The $962 reported for 2025 was more than what 91% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $111 · 2021: $602 · 2022: $1,072 · 2023: $1,156 · 2024: $1,194 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,311.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $706.42 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $590.18 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $326.99 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Otsuka America Pharmaceutical, INC. | $324.48 | 2022-2025 | Rexulti |
| Abbvie INC. | $258.46 | 2021-2023 | Vraylar, Qulipta, Viberzi |
| Astellas Pharma US INC | $230.82 | 2020-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $188.02 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.73 | 2019-2024 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $177.04 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.42 | 2019-2024 | Xifaxan |
| Boston Scientific Corporation | $148.97 | 2024 | Watchman Flx |
| Lundbeck LLC | $146.15 | 2022-2025 | Rexulti |
| Abbott Laboratories | $142.49 | 2021-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $137.42 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $115.26 | 2021-2025 | Eliquis |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Blank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.